| Name | Title | Contact Details |
|---|---|---|
Gregg Nyberg |
Chief Technology Officer | Profile |
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
Seventh Wave is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bio-Kinetic Clinical Applications is a Springfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Receptor Life Sciences, Inc. develops inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders.
SiChuan Sanherb Biotech is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.